论文部分内容阅读
心血管疾病是尿毒症维持血透患者最主要的死亡原因。其中尤以左心室肥厚的发生率和病死率为高。本研究主要探讨重组人红细胞生成素对左心室肥厚的影响,以及该药物治疗性高血压对此影响有无对抗作用。 1 材料与方法 1.1 研究对象 实验组30例,男21例,女9例,平均年龄54.2±10.6岁,均为尿毒症行血液透析者,平均透析次数116.5±30.8次,每周透析3次,每次4小时。其肾脏原发病为:慢性肾小球肾炎21例,糖尿病肾病3例,IgA肾病2例,狼疮性肾炎2例,慢性肾盂肾炎2
Cardiovascular disease is uremia to maintain hemodialysis patients the most important cause of death. In particular, the incidence and mortality of left ventricular hypertrophy is high. This study focused on the impact of recombinant human erythropoietin on left ventricular hypertrophy, and the therapeutic effect of the drug on whether there is antagonism. 1 Materials and Methods 1.1 Subjects The experimental group of 30 patients, 21 males and 9 females, mean age 54.2 ± 10.6 years, were uremic hemodialysis patients, the average number of dialysis 116.5 ± 30.8 times a week dialysis 3 times, 4 hours each time. The primary kidney disease: 21 cases of chronic glomerulonephritis, diabetic nephropathy in 3 cases, IgA nephropathy in 2 cases, 2 cases of lupus nephritis, chronic pyelonephritis 2